Calithera Reports Phase 2 CANTATA Trial of Telaglenastat for Advanced Renal Cell Carcinoma Fails to Reach Primary Endpoint
Calithera Biosciences announced topline results from the CANTATA clinical study, which was designed to evaluate the company’s glutaminase inhibitor telaglenastat […]